Stem definition | Drug id | CAS RN |
---|---|---|
4585 | 587-26-8 |
Molecule | Description |
---|---|
Synonyms:
|
a phosphate binder used for hyperphosphatemia treatment in end-stage renal disease
|
Dose | Unit | Route |
---|---|---|
2.25 | g | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 26, 2004 | FDA | SHIRE LLC | |
Oct. 16, 2008 | PMDA | Bayer Yakuhin |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Shunt stenosis | 340.88 | 23.89 | 51 | 2735 | 489 | 63485747 |
Shunt occlusion | 249.24 | 23.89 | 40 | 2746 | 625 | 63485611 |
Nephrogenic systemic fibrosis | 125.73 | 23.89 | 31 | 2755 | 4525 | 63481711 |
Blood phosphorus increased | 79.73 | 23.89 | 20 | 2766 | 3125 | 63483111 |
Peritonitis | 74.14 | 23.89 | 28 | 2758 | 17126 | 63469110 |
Skin induration | 69.43 | 23.89 | 18 | 2768 | 3205 | 63483031 |
Blood parathyroid hormone increased | 51.33 | 23.89 | 14 | 2772 | 3024 | 63483212 |
Skin hypertrophy | 49.80 | 23.89 | 14 | 2772 | 3377 | 63482859 |
Skin tightness | 46.47 | 23.89 | 14 | 2772 | 4302 | 63481934 |
Peripheral arterial occlusive disease | 42.54 | 23.89 | 13 | 2773 | 4188 | 63482048 |
Skin fibrosis | 40.12 | 23.89 | 9 | 2777 | 871 | 63485365 |
Death | 37.15 | 23.89 | 62 | 2724 | 374319 | 63111917 |
Angina unstable | 32.16 | 23.89 | 12 | 2774 | 7083 | 63479153 |
Hypocalcaemia | 32.11 | 23.89 | 19 | 2767 | 31694 | 63454542 |
Shunt malfunction | 31.13 | 23.89 | 5 | 2781 | 78 | 63486158 |
Joint contracture | 29.38 | 23.89 | 8 | 2778 | 1716 | 63484520 |
Dialysis | 27.68 | 23.89 | 12 | 2774 | 10415 | 63475821 |
Scar | 27.51 | 23.89 | 13 | 2773 | 13769 | 63472467 |
Vomiting | 27.20 | 23.89 | 69 | 2717 | 559548 | 62926688 |
Ileus | 26.70 | 23.89 | 13 | 2773 | 14712 | 63471524 |
Peritonitis bacterial | 24.88 | 23.89 | 9 | 2777 | 4870 | 63481366 |
Shunt infection | 24.21 | 23.89 | 4 | 2782 | 75 | 63486161 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Appendicolith | 487.90 | 22.87 | 144 | 7290 | 8457 | 34941040 |
Shunt stenosis | 427.07 | 22.87 | 82 | 7352 | 700 | 34948797 |
Appendicitis | 426.39 | 22.87 | 148 | 7286 | 14659 | 34934838 |
Cardiogenic shock | 335.51 | 22.87 | 146 | 7288 | 26472 | 34923025 |
Stress | 323.43 | 22.87 | 148 | 7286 | 30199 | 34919298 |
Shunt occlusion | 270.03 | 22.87 | 57 | 7377 | 813 | 34948684 |
Ascites | 266.16 | 22.87 | 149 | 7285 | 46422 | 34903075 |
Abdominal distension | 257.47 | 22.87 | 158 | 7276 | 58334 | 34891163 |
Ventricular fibrillation | 244.56 | 22.87 | 112 | 7322 | 22842 | 34926655 |
Multiple organ dysfunction syndrome | 198.34 | 22.87 | 149 | 7285 | 76417 | 34873080 |
Hyponatraemia | 186.00 | 22.87 | 148 | 7286 | 82543 | 34866954 |
Constipation | 167.54 | 22.87 | 174 | 7260 | 136808 | 34812689 |
General physical health deterioration | 151.53 | 22.87 | 160 | 7274 | 128109 | 34821388 |
Abdominal pain | 148.74 | 22.87 | 178 | 7256 | 163440 | 34786057 |
Sepsis | 142.92 | 22.87 | 176 | 7258 | 166385 | 34783112 |
Vomiting | 126.49 | 22.87 | 204 | 7230 | 247417 | 34702080 |
Dry mouth | 106.38 | 22.87 | 71 | 7363 | 30094 | 34919403 |
Myasthenia gravis | 90.27 | 22.87 | 39 | 7395 | 6901 | 34942596 |
X-ray abnormal | 85.64 | 22.87 | 20 | 7414 | 461 | 34949036 |
Nausea | 85.38 | 22.87 | 208 | 7226 | 339700 | 34609797 |
Blood uric acid increased | 84.04 | 22.87 | 41 | 7393 | 9583 | 34939914 |
Peripheral arterial occlusive disease | 76.36 | 22.87 | 33 | 7401 | 5841 | 34943656 |
Hyperphosphataemia | 67.92 | 22.87 | 28 | 7406 | 4409 | 34945088 |
Drug therapy | 51.28 | 22.87 | 16 | 7418 | 1125 | 34948372 |
Analgesic therapy | 49.10 | 22.87 | 15 | 7419 | 983 | 34948514 |
Blood cholesterol increased | 48.64 | 22.87 | 38 | 7396 | 20505 | 34928992 |
Product residue present | 47.77 | 22.87 | 19 | 7415 | 2727 | 34946770 |
Incorrect route of product administration | 47.67 | 22.87 | 33 | 7401 | 14812 | 34934685 |
Acute kidney injury | 47.29 | 22.87 | 5 | 7429 | 304983 | 34644514 |
Nephrogenic systemic fibrosis | 47.19 | 22.87 | 21 | 7413 | 3984 | 34945513 |
Shunt infection | 45.37 | 22.87 | 9 | 7425 | 92 | 34949405 |
Sleep disorder therapy | 44.53 | 22.87 | 14 | 7420 | 1009 | 34948488 |
Fatigue | 39.21 | 22.87 | 15 | 7419 | 370638 | 34578859 |
X-ray gastrointestinal tract abnormal | 37.28 | 22.87 | 5 | 7429 | 0 | 34949497 |
Blood phosphorus increased | 36.76 | 22.87 | 22 | 7412 | 7699 | 34941798 |
Somnolence | 36.60 | 22.87 | 76 | 7358 | 111040 | 34838457 |
Iron deficiency | 35.55 | 22.87 | 19 | 7415 | 5362 | 34944135 |
Dialysis hypotension | 34.70 | 22.87 | 6 | 7428 | 26 | 34949471 |
Haemoglobin increased | 34.25 | 22.87 | 16 | 7418 | 3393 | 34946104 |
Peritonitis | 33.90 | 22.87 | 28 | 7406 | 16337 | 34933160 |
Drug ineffective | 32.19 | 22.87 | 30 | 7404 | 456721 | 34492776 |
Hyperparathyroidism secondary | 31.34 | 22.87 | 12 | 7422 | 1556 | 34947941 |
Blood parathyroid hormone increased | 28.17 | 22.87 | 11 | 7423 | 1503 | 34947994 |
Shunt aneurysm | 28.17 | 22.87 | 5 | 7429 | 26 | 34949471 |
Aplasia pure red cell | 27.97 | 22.87 | 17 | 7417 | 6115 | 34943382 |
Wrong technique in product usage process | 27.45 | 22.87 | 36 | 7398 | 35950 | 34913547 |
Hypophosphataemia | 27.41 | 22.87 | 21 | 7413 | 11005 | 34938492 |
Condition aggravated | 27.05 | 22.87 | 96 | 7338 | 192100 | 34757397 |
Neuralgia | 25.50 | 22.87 | 23 | 7411 | 15090 | 34934407 |
Bacterial infection | 25.00 | 22.87 | 24 | 7410 | 17039 | 34932458 |
Hypocalcaemia | 24.53 | 22.87 | 28 | 7406 | 24261 | 34925236 |
Gangrene | 24.28 | 22.87 | 14 | 7420 | 4572 | 34944925 |
Mucosal atrophy | 23.31 | 22.87 | 5 | 7429 | 77 | 34949420 |
Peritonitis bacterial | 23.01 | 22.87 | 15 | 7419 | 6095 | 34943402 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Shunt stenosis | 756.48 | 20.85 | 133 | 9446 | 1258 | 79733551 |
Appendicolith | 564.94 | 20.85 | 143 | 9436 | 8408 | 79726401 |
Shunt occlusion | 494.56 | 20.85 | 94 | 9485 | 1410 | 79733399 |
Appendicitis | 463.82 | 20.85 | 149 | 9430 | 20645 | 79714164 |
Cardiogenic shock | 351.70 | 20.85 | 146 | 9433 | 41768 | 79693041 |
Ascites | 278.04 | 20.85 | 149 | 9430 | 75413 | 79659396 |
Ventricular fibrillation | 273.76 | 20.85 | 113 | 9466 | 31813 | 79702996 |
Stress | 270.74 | 20.85 | 149 | 9430 | 79463 | 79655346 |
Abdominal distension | 233.82 | 20.85 | 157 | 9422 | 119493 | 79615316 |
Multiple organ dysfunction syndrome | 207.10 | 20.85 | 146 | 9433 | 120100 | 79614709 |
Sepsis | 181.76 | 20.85 | 191 | 9388 | 269237 | 79465572 |
Hyponatraemia | 164.58 | 20.85 | 150 | 9429 | 177698 | 79557111 |
Constipation | 158.48 | 20.85 | 182 | 9397 | 282868 | 79451941 |
General physical health deterioration | 152.43 | 20.85 | 176 | 9403 | 275062 | 79459747 |
Abdominal pain | 142.97 | 20.85 | 203 | 9376 | 389366 | 79345443 |
Peripheral arterial occlusive disease | 127.76 | 20.85 | 45 | 9534 | 8213 | 79726596 |
Vomiting | 125.82 | 20.85 | 258 | 9321 | 665570 | 79069239 |
Nephrogenic systemic fibrosis | 104.65 | 20.85 | 36 | 9543 | 6124 | 79728685 |
Myasthenia gravis | 96.53 | 20.85 | 39 | 9540 | 10360 | 79724449 |
Hyperphosphataemia | 92.01 | 20.85 | 33 | 9546 | 6343 | 79728466 |
Blood uric acid increased | 90.32 | 20.85 | 40 | 9539 | 13320 | 79721489 |
Peritonitis | 75.12 | 20.85 | 45 | 9534 | 27991 | 79706818 |
Product residue present | 73.28 | 20.85 | 24 | 9555 | 3512 | 79731297 |
Dry mouth | 73.07 | 20.85 | 70 | 9509 | 87949 | 79646860 |
Shunt infection | 68.09 | 20.85 | 13 | 9566 | 199 | 79734610 |
Nausea | 66.58 | 20.85 | 258 | 9321 | 956938 | 78777871 |
X-ray abnormal | 65.18 | 20.85 | 25 | 9554 | 5788 | 79729021 |
Blood parathyroid hormone increased | 61.90 | 20.85 | 21 | 9558 | 3424 | 79731385 |
Drug therapy | 59.50 | 20.85 | 16 | 9563 | 1185 | 79733624 |
Analgesic therapy | 57.41 | 20.85 | 15 | 9564 | 994 | 79733815 |
Fatigue | 52.75 | 20.85 | 23 | 9556 | 929704 | 78805105 |
Skin induration | 52.67 | 20.85 | 20 | 9559 | 4505 | 79730304 |
Sleep disorder therapy | 52.42 | 20.85 | 14 | 9565 | 1010 | 79733799 |
Angina unstable | 50.79 | 20.85 | 29 | 9550 | 16498 | 79718311 |
Blood phosphorus increased | 48.33 | 20.85 | 24 | 9555 | 10323 | 79724486 |
Drug ineffective | 48.13 | 20.85 | 36 | 9543 | 1080877 | 78653932 |
Incorrect route of product administration | 47.80 | 20.85 | 37 | 9542 | 34892 | 79699917 |
Hypocalcaemia | 47.78 | 20.85 | 43 | 9536 | 49881 | 79684928 |
Skin hypertrophy | 47.52 | 20.85 | 19 | 9560 | 4909 | 79729900 |
Haemoglobin increased | 46.79 | 20.85 | 20 | 9559 | 6112 | 79728697 |
X-ray gastrointestinal tract abnormal | 45.73 | 20.85 | 6 | 9573 | 3 | 79734806 |
Shunt aneurysm | 43.49 | 20.85 | 7 | 9572 | 36 | 79734773 |
Acute kidney injury | 40.24 | 20.85 | 7 | 9572 | 519397 | 79215412 |
Somnolence | 39.47 | 20.85 | 88 | 9491 | 238893 | 79495916 |
Cerebral infarction | 39.16 | 20.85 | 37 | 9542 | 45639 | 79689170 |
Aplasia pure red cell | 39.11 | 20.85 | 19 | 9560 | 7791 | 79727018 |
Shunt malfunction | 36.07 | 20.85 | 8 | 9571 | 263 | 79734546 |
Skin tightness | 35.61 | 20.85 | 16 | 9563 | 5506 | 79729303 |
Hyperparathyroidism secondary | 35.50 | 20.85 | 13 | 9566 | 2647 | 79732162 |
Diverticulum intestinal haemorrhagic | 33.66 | 20.85 | 14 | 9565 | 3997 | 79730812 |
Iron deficiency | 33.55 | 20.85 | 19 | 9560 | 10635 | 79724174 |
Peritonitis bacterial | 32.69 | 20.85 | 18 | 9561 | 9549 | 79725260 |
Mucosal atrophy | 32.63 | 20.85 | 6 | 9573 | 74 | 79734735 |
Joint contracture | 32.45 | 20.85 | 12 | 9567 | 2512 | 79732297 |
Ileus | 32.07 | 20.85 | 26 | 9553 | 26185 | 79708624 |
Dialysis hypotension | 31.93 | 20.85 | 6 | 9573 | 84 | 79734725 |
Hypophosphataemia | 31.47 | 20.85 | 23 | 9556 | 19890 | 79714919 |
Gangrene | 31.00 | 20.85 | 17 | 9562 | 8947 | 79725862 |
Dialysis | 30.72 | 20.85 | 22 | 9557 | 18440 | 79716369 |
Wrong technique in product usage process | 30.68 | 20.85 | 41 | 9538 | 73834 | 79660975 |
Bacterial infection | 30.03 | 20.85 | 27 | 9552 | 31253 | 79703556 |
Shunt blood flow excessive | 27.40 | 20.85 | 4 | 9575 | 9 | 79734800 |
Skin fibrosis | 26.24 | 20.85 | 9 | 9570 | 1515 | 79733294 |
Large intestine polyp | 25.51 | 20.85 | 17 | 9562 | 12691 | 79722118 |
Cardiac failure | 25.51 | 20.85 | 57 | 9522 | 154785 | 79580024 |
Toxicity to various agents | 24.50 | 20.85 | 10 | 9569 | 421530 | 79313279 |
Joint swelling | 24.38 | 20.85 | 3 | 9576 | 288643 | 79446166 |
Blood cholesterol increased | 23.96 | 20.85 | 39 | 9540 | 83681 | 79651128 |
Fibrosis | 23.86 | 20.85 | 12 | 9567 | 5297 | 79729512 |
Sudden death | 22.74 | 20.85 | 20 | 9559 | 22491 | 79712318 |
Gastric mucosal lesion | 21.91 | 20.85 | 7 | 9572 | 946 | 79733863 |
Renal cyst infection | 21.40 | 20.85 | 5 | 9574 | 208 | 79734601 |
Bezoar | 21.28 | 20.85 | 9 | 9570 | 2679 | 79732130 |
Enterocolitis | 21.22 | 20.85 | 16 | 9563 | 14496 | 79720313 |
Neuralgia | 21.20 | 20.85 | 23 | 9556 | 33361 | 79701448 |
Weight increased | 20.89 | 20.85 | 4 | 9575 | 277382 | 79457427 |
None
Source | Code | Description |
---|---|---|
ATC | V03AE03 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Renal Osteodystrophy with Hyperphosphatemia | indication | ||
Hyperphosphatemia associated with administration of FGFR inhibitor | indication | ||
Constipation | contraindication | 14760008 | DOID:2089 |
Fecal impaction | contraindication | 44635007 | |
Intestinal obstruction | contraindication | 81060008 | DOID:8437 |
Gastrointestinal obstruction | contraindication | 126765001 |
None
None
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 1GM BASE | FOSRENOL | TAKEDA PHARMS USA | N021468 | Nov. 23, 2005 | RX | TABLET, CHEWABLE | ORAL | 7381428 | Aug. 26, 2024 | REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE |
EQ 250MG BASE | FOSRENOL | TAKEDA PHARMS USA | N021468 | Oct. 26, 2004 | DISCN | TABLET, CHEWABLE | ORAL | 7381428 | Aug. 26, 2024 | REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE |
EQ 500MG BASE | FOSRENOL | TAKEDA PHARMS USA | N021468 | Oct. 26, 2004 | RX | TABLET, CHEWABLE | ORAL | 7381428 | Aug. 26, 2024 | REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE |
EQ 750MG BASE | FOSRENOL | TAKEDA PHARMS USA | N021468 | Nov. 23, 2005 | RX | TABLET, CHEWABLE | ORAL | 7381428 | Aug. 26, 2024 | REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE |
None
None
ID | Source |
---|---|
4021512 | VUID |
N0000179691 | NUI |
4021512 | VANDF |
CHEMBL2096647 | ChEMBL_ID |
C119467 | MESH_SUPPLEMENTAL_RECORD_UI |
DB06792 | DRUGBANK_ID |
490D9F069T | UNII |
234416 | RXNORM |
18979 | MMSL |
35731 | MMSL |
62060 | MMSL |
79763 | MMSL |
d05395 | MMSL |
008767 | NDDF |
414570008 | SNOMEDCT_US |
414571007 | SNOMEDCT_US |
C0768119 | UMLSCUI |
168924 | PUBCHEM_CID |
54451-24-0 | SECONDARY_CAS_RN |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5938 | TABLET, CHEWABLE | 500 mg | ORAL | ANDA | 27 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5939 | TABLET, CHEWABLE | 750 mg | ORAL | ANDA | 27 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-5940 | TABLET, CHEWABLE | 1000 mg | ORAL | ANDA | 27 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-252 | TABLET, CHEWABLE | 500 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-252 | TABLET, CHEWABLE | 500 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-253 | TABLET, CHEWABLE | 750 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-253 | TABLET, CHEWABLE | 750 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-254 | TABLET, CHEWABLE | 1000 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-254 | TABLET, CHEWABLE | 1000 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-256 | POWDER | 750 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-256 | POWDER | 750 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-257 | POWDER | 1000 mg | ORAL | NDA | 31 sections |
Fosrenol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-257 | POWDER | 1000 mg | ORAL | NDA | 31 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-422 | TABLET, CHEWABLE | 500 mg | ORAL | NDA authorized generic | 31 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-422 | TABLET, CHEWABLE | 500 mg | ORAL | NDA authorized generic | 31 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-423 | TABLET, CHEWABLE | 750 mg | ORAL | NDA authorized generic | 31 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-423 | TABLET, CHEWABLE | 750 mg | ORAL | NDA authorized generic | 31 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-424 | TABLET, CHEWABLE | 1000 mg | ORAL | NDA authorized generic | 31 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-424 | TABLET, CHEWABLE | 1000 mg | ORAL | NDA authorized generic | 31 sections |
Lanthanum Carbonate | Human Prescription Drug Label | 1 | 68180-819 | TABLET, CHEWABLE | 500 mg | ORAL | ANDA | 26 sections |
Lanthanum Carbonate | Human Prescription Drug Label | 1 | 68180-820 | TABLET, CHEWABLE | 750 mg | ORAL | ANDA | 26 sections |
Lanthanum Carbonate | Human Prescription Drug Label | 1 | 68180-821 | TABLET, CHEWABLE | 1000 mg | ORAL | ANDA | 26 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-934 | TABLET, CHEWABLE | 500 mg | ORAL | ANDA | 30 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-934 | TABLET, CHEWABLE | 500 mg | ORAL | ANDA | 30 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-935 | TABLET, CHEWABLE | 750 mg | ORAL | ANDA | 30 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-935 | TABLET, CHEWABLE | 750 mg | ORAL | ANDA | 30 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-936 | TABLET, CHEWABLE | 1000 mg | ORAL | ANDA | 30 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-936 | TABLET, CHEWABLE | 1000 mg | ORAL | ANDA | 30 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76282-476 | TABLET, CHEWABLE | 500 mg | ORAL | ANDA | 30 sections |
Lanthanum carbonate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76282-476 | TABLET, CHEWABLE | 500 mg | ORAL | ANDA | 30 sections |